US FDA’s Prasad: ‘We Will Always Embrace Surrogate Endpoints’

 
• By Sarah Karlin-Smith

The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.

Vinay Prasad
CBER Director Vinay Prasad discussed accelerated approval and cancer with FDA Commissioner Martin Makary after a 20 May presentation. (US FDA webstream)

More from US FDA

More from R&D